Table 1.

2-AAF–induced tumor development in p53.S389A mice

Dose 2-AAF (in ppm)Genotype
Wild-typep53S389A/+p53S389A/S389Ap53S389A/−p53+/−
03000300030003000300
Urinary bladder
    Number examined1030925102810261026
        Atypia1351211
        Transitional cell papilloma322
        Carcinoma in situ12
        Transitional cell carcinoma28
Tumor incidence (%)0000014 *023 *038 *,
Liver
    Number examined10301025102710261029
        Hypertrophy/pleomorphisms
        Hepatocellular adenoma21113
        Hepatocellular carcinoma13
Tumor incidence (%)070400081021
  • NOTE: Tumor incidences were calculated by dividing the total number of tumors (either transitional cell papilloma, carcinoma in situ and transitional cell carcinomas in urinary bladder, or hepatocellular adenomas and carcinomas) by the number of mice examined.

  • * P ≤ 0.05 as compared with 2-AAF–treated wild-type mice.

  • P ≤ 0.05 as compared with untreated control mice.